{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "FlublokPI",
  "verification_stats": {
    "total_extracted": 3,
    "verified": 0,
    "rejected": 3,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "5. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Vol. 297, pp. 1577-1582.",
      "reason": "does not support claim",
      "original_explanation": "This reference is cited in the context of clinical studies comparing the immunogenicity (antibody response) of recombinant hemagglutinin (rHA) vaccines, such as Flublok, to standard egg-based vaccines, directly supporting the claim about robust antibody responses."
    },
    {
      "id": 2,
      "quote": "3. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine 2009 Vol. 28, pp. 379\u2013385.",
      "reason": "does not support claim",
      "original_explanation": "This reference is cited as a comparative study of the immunogenicity of recombinant (higher-dose) and standard egg-based influenza vaccines in older adults, supporting the claim that the recombinant vaccine may induce a more robust antibody response."
    },
    {
      "id": "comp_1",
      "quote": "2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of Flublok trivalent recombinant baculovirus expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "reason": "does not support claim",
      "original_explanation": "This reference describes a study that evaluated the immunogenicity of Flublok, a higher-dose recombinant flu vaccine, in adults aged 50-64. The focus on immunogenicity directly relates to the claim about a more robust antibody response compared to standard egg-based vaccines."
    }
  ],
  "model_used": "gpt-4.1"
}